title: Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer.
abstract: OBJECTIVE
  Elderly patients with small cell lung cancer (SCLC) and/or those with comorbid conditions are frequently not considered candidates for standard combination chemotherapy. An active, but less toxic regimen is needed for this group of patients.
  
  
  METHODS
  Forty-seven elderly (> 65 years) or medically unfit patients with SCLC were treated with oral etoposide 100 mg/m2 x 7 days and carboplatin 150 mg/m2 day 1. Treatment was given every 3-4 weeks for six cycles in responding patients. Patients responding to the chemotherapy regimen were also treated with prophylactic cranial irradiation, and limited-stage patients received thoracic radiotherapy. The study population included 36 extensive-stage patients and 11 limited-disease patients with renal or cardiac disease that precluded standard chemotherapy. The median age of the study population was 69 years (range: 47-84).
  
  
  RESULTS
  Nine of 47 patients were inevaluable for response, including four patients who succumbed to sepsis. Of the 38 patients evaluable for response, 71% responded (95% CI: 56-86%) (88% LD; 67% ED) with a complete response in 29% of patients (50% LD; 23% ED). Based on an analysis of intent to treat, the overall response rate was 60% and the median survival time of the whole group was 46 weeks (LD, 59 weeks; ED, 45 weeks). Treatment was generally well tolerated. Neutropenia was the dose-limiting toxicity; the median nadir granulocyte count was 1.04 x 10(9)/L (range: 0-8.2).
  
  
  CONCLUSIONS
  We conclude that this regimen can provide palliation to SCLC patients who might not otherwise be considered for systemic chemotherapy.
authors.affiliation: University of Ottawa, Ontario, Canada.
authors.forename: W K
authors.initials: WK
authors.lastname: Evans
authors.forename: A
authors.initials: A
authors.lastname: Radwi
authors.forename: E
authors.initials: E
authors.lastname: Tomiak
authors.forename: D M
authors.initials: DM
authors.lastname: Logan
authors.forename: H
authors.initials: H
authors.lastname: Martins
authors.forename: D J
authors.initials: DJ
authors.lastname: Stewart
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: J A
authors.initials: JA
authors.lastname: Maroun
authors.forename: S
authors.initials: S
authors.lastname: Dahrouge
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016330:Frail Elderly; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D005047:Etoposide; D016190:Carboplatin